Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
The pilot study aimed to assess the safety and efficacy of the per-transplant ruxolitinib strategy. In terms of safe, Ali says that strategy was well-tolerated, with most of the toxicities being grade 1 in severity. Few patients experienced grade 2 or 3 toxicities, which included renal failure and cardiac arrest in 2 patients. These events were not related to ruxolitinib, Ali explains.
Results also showed that the incidence of high-grade graft-versus-host disease was low in this study. These findings confirm the original hypothesis of the study.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More